Relay Therapeutics (RLAY) Operating Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has reported Operating Expenses for 8 consecutive years, with $81.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 11.84% year-over-year to $81.6 million; the TTM figure through Mar 2026 stood at $307.1 million (down 18.02% YoY), while the FY2025 annual figure was $318.1 million, down 16.83% from the prior year.
• Operating Expenses climbed to $81.6 million in Q1 2026 per RLAY's latest filing, from $67.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $106.2 million in Q2 2023 and bottomed at $63.1 million in Q1 2022.
• Historically, Operating Expenses has averaged $87.1 million across 5 years, with a median of $86.2 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Expenses sank 59.79% — and 2023, when it jumped 60.6%.
• Relay Therapeutics' Operating Expenses stood at $73.1 million in 2022, then advanced by 26.11% to $92.2 million in 2023, then slipped by 7.83% to $85.0 million in 2024, then dropped by 20.42% to $67.6 million in 2025, then increased by 20.64% to $81.6 million in 2026.
• Business Quant data shows RLAY's Operating Expenses at $81.6 million in Q1 2026, $67.6 million in Q4 2025, and $80.4 million in Q3 2025.